How to assess the benefit-risk balance of drugs? Some lessons from COVID

Conference Scientific and technical culture
September 16, 2025Saint-Martin-d'Hères - University campus

Every month, the Bibliothèque Universitaire Joseph-Fourier hosts a workshop to disseminate scientific culture: la science infuse.

Jean-Luc Cracowski, Professor of Pharmacology and Hospital Practitioner at Grenoble Alpes University and President of the National College of Medical Pharmacology, shares his expertise on the risk-benefit balance of a drug.


The benefit of a drug is assessed in a clinical trial. However, once a drug is on the market, its rare adverse effects may not be known and need to be monitored by the pharmacovigilance system. How can we reconcile bringing effective drugs to market within a reasonable timeframe and analyzing their risks? Does it make sense to use the scales to assess the benefits and risks of medicines? The Covid experience will be used to illustrate these concepts.

 

Published August 22, 2025
Updated September 12, 2025